GlucoSense's Lumina Patch Passes FDA Review: The First Needle-Free Continuous Glucose Monitor

Boston — The U.S. Food and Drug Administration has granted 510(k) clearance to GlucoSense's Lumina continuous glucose monitoring (CGM) system, making it the first non-invasive device of its kind to receive regulatory approval in the United States. The clearance follows a pivotal clinical trial involving 1,814 participants across 22 clinical sites, published today in the New England Journal of Medicine.

Existing CGM systems require a subdermal filament — a small electrode inserted under the skin — to measure interstitial fluid glucose levels. While effective, the requirement for needle insertion has limited adoption among type 2 patients, who constitute the vast majority of the diabetic population. Lumina eliminates this barrier entirely by using mid-infrared spectroscopy (MIRS) to measure glucose concentrations through the skin's surface.

How Lumina Works

The Lumina is a 28-gram adhesive patch worn on the upper arm. Its central component is an array of quantum cascade lasers (QCLs) emitting at glucose absorption wavelengths between 8-10 micrometers. A detector array measures the attenuated reflected light and an on-patch processor runs a calibration algorithm trained on the individual patient's baseline blood glucose readings.

Users perform a finger-stick blood glucose calibration twice daily — the same as many existing CGMs — and the device requires a warm-up period of approximately 45 minutes after initial application. The patch lasts seven days before replacement, which GlucoSense says is limited by the on-patch battery rather than any consumable chemistry.

Clinical Trial Results

The NEJM paper reports that Lumina's mean absolute relative difference (MARD) against reference blood glucose measurements was 12.4% — higher than the best needle-based CGMs (which can achieve sub-9% MARD) but well within the 15% threshold the FDA considers acceptable for CGM equivalence for dosing decisions.

Importantly, the device showed consistent performance across different skin tones and body mass index categories, addressing a long-standing concern about spectroscopic glucose sensing bias. Subgroup analysis showed MARD ranging from 11.8% in the lightest skin tone cohort to 13.1% in the darkest — a narrower range than the optical performance variance typically seen in pulse oximetry across skin tones.

Impact on Diabetes Care

The non-invasive form factor could significantly expand CGM adoption among the 38 million Americans with diabetes, the majority of whom have type 2 disease. Currently, fewer than 20% of type 2 diabetics on insulin therapy use CGM, and the rate is far lower among non-insulin-using type 2 patients. Cost and needle aversion are cited as the two primary barriers.

GlucoSense has not announced pricing, but industry analysts expect the Lumina to be priced at a premium to existing CGMs, which typically cost $1,000-1,500 per month including sensors and transmitter hardware. The company says it is in discussions with major insurers and Medicare Advantage plans regarding coverage.

Dexcom and Abbott Response

Dexcom, whose G7 CGM dominates the US market, declined to comment specifically on Lumina but noted that its next-generation platform is "on track for regulatory submission." Abbott's FreeStyle Libre franchise — the market leader in Europe — is widely expected to accelerate its own non-invasive development program in response. Abbott shares fell 4.2% in after-hours trading following the announcement.

---

NextPaper covers the business and policy implications of non-invasive CGM in our Medical Technology section.